Rakesh Kumar, a researcher with six recent corrections and one retraction, has had one of those corrections upgraded to a retraction.
Here’s the unhelpful notice, from Molecular Endocrinology: Continue reading Cancer researcher has correction upgraded to retraction
Try to follow along on this one. We think it’s worth it.
The authors of a letter replying to a comment in a urology journal have retracted their response because it contained inappropriate figures. At least, that’s the official story.
The original paper, “Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy,” came from a group at Weill Medical College of Cornell University led by Ashutosh Tewari. Published in July 2012 in European Urology, it purported to find that: Continue reading “Our jaws hit the floor!!” Researchers say authors doctored images for rebuttal letter
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:
Continue reading MD Anderson postdoc faked results of Novartis anti-cancer compound study
A research team at the University of Texas-Southwestern that has retracted eight papers for image manipulation has retracted another, this one in Lung Cancer.
Here’s the notice for “Aberrant methylation of Reprimo in lung cancer,” published by Adi Gazdar’s group: Continue reading UT-Southwestern cancer research group notches ninth retraction
A paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.
Here’s the notice from the International Journal of Cancer about a 2007 paper purporting to show that the substance, GcMAF, is useful against breast cancer: Continue reading Paper about widely touted but unapproved “cure” for cancer, autism retracted
A group of researchers in China has lost their paper on liver cancer after the first author admitted to duplication, also known, inelegantly, as self-plagiarism.
The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.
According to the abstract: Continue reading “Lack of experience and understanding” forces duplication retractions of liver cancer paper
PLOS ONE has retracted a 2012 article by a group of breast cancer researchers after another scientist — a leading U.S. oncologist — objected that the data came from his lab.
The paper, “GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer,” came from a team composed of researchers at the Morehouse School of Medicine, Xavier University of Louisiana and the University of Miami School of Medicine. It purported to find that: Continue reading PLOS ONE retracts breast cancer genetics paper after claim of misappropriated data
A group of urologists in China has lost their 2012 paper in the Journal of Surgical Research because one of the authors was evidently rather naughty.
The article, “Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study,” purported to show that: Continue reading Misconduct prompts retraction of prostatectomy paper
The editors of PLoS ONE have issued an Expression of Concern (which seems likely to become a retraction) for a 2014 paper by a group of researchers in China who claim to have been led astray by a contractor hired to “edit the language” of the report.
The article, “Arsenic Sulfide Promotes Apoptosis in Retinoid Acid Resistant Human Acute Promyelocytic Leukemic NB4-R1 Cells through Downregulation of SET Protein,” came from a group in the Department of Hematology at the First Affiliated Hospital at Xi’an Jiaotong University, and was led by Yuwang Tian, a pathologist at the General Hospital of Beijing Military Area of PLA.
Or at least that’s what the manuscript eventually said. According to the expression of concern, however, that’s not what it said initially: Continue reading Wayward “contractor” prompts expression of concern for PLoS ONE paper on cancer cells
Alfredo Fusco, who is under criminal investigation in Italy for scientific fraud, has had two more papers retracted.
Both are in the Journal of Biological Chemistry (JBC). Here are the two studies: Continue reading Cancer researcher facing criminal inquiry up to six retractions